RIPK1 protects from TNF-α-mediated liver damage during hepatitis

Cell Death and Disease

Volumn 7, Issue 11, 2016, Pages

  Filliol, Aveline ^a,b   Piquet Pellorce, Claire ^a,b   Le Seyec, Jacques ^a,b   Farooq, Muhammad ^a,b   Genet, Valentine ^a,b   Lucas Clerc, Catherine ^a   Bertin, John ^c   Gough, Peter J ^c   Dimanche Boitrel, Marie Thérèse ^a,b   Vandenabeele, Peter ^d,e   Bertrand, Mathieu J M ^d,e   Samson, Michel ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c GLAXOSMITHKLINE   (United States)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CONCANAVALIN A; PROTEIN; RIPK1 KINASE PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; PROTECTIVE AGENT; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS; HOMEOSTASIS; LIVER CELL; LIVER INJURY; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL CULTURE; COMPLICATION; INFLAMMATION; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CONCANAVALIN A; HEPATITIS; HEPATOCYTES; HOMEOSTASIS; INFLAMMATION; LIVER; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PROTECTIVE AGENTS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84995378013     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.362     Document Type: Article

References (52)

1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38: S38-S53.
2. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014; 147: 765-783 e764.
3. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59: 583-594.
4. Arshad MI, Piquet-Pellorce C, L'Helgoualc'h A, Rauch M, Patrat-Delon S, Ezan F et al. TRAIL but not FasL and TNFalpha, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 2012; 56: 2353-2362.
5. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311-320.
6. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988; 2: 72-74.
7. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-920.
8. Morioka S, Broglie P, Omori E, Ikeda Y, Takaesu G, Matsumoto K et al. TAK1 kinase switches cell fate from apoptosis to necrosis following TNF stimulation. J Cell Biol 2014; 204: 607-623.
9. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297-303.
10. Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014; 192: 5476-5480.
11. Takahashi N, Vereecke L, Bertrand MJ, Duprez L, Berger SB, Divert T et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 2014; 513: 95-99.
12. Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513: 90-94.
13. Roderick JE, Hermance N, Zelic M, Simmons MJ, Polykratis A, Pasparakis M et al. Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. Proc Natl Acad Sci USA 2014; 111: 14436-14441.
14. Tiegs G, Hentschel J, Wendel AA. T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196-203.
15. Arshad MI, Rauch M, L'Helgoualc'h A, Julia V, Leite-de-Moraes MC, Lucas-Clerc C et al. NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis. Eur J Immunol 2011; 41: 2341-2348.
16. Watanabe Y, Morita M, Akaike T. Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury. Hepatology 1996; 24: 702-710.
17. Tagawa Y, Kakuta S, Iwakura Y. Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur J Immunol 1998; 28: 4105-4113.
18. Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kunstle G et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997; 27: 2870-2875.
19. Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, Van Herreweghe F et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ 2012; 19: 2003-2014.
20. Zhou Y, Dai W, Lin C, Wang F, He L, Shen M et al. Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm 2013; 2013: 1-15.
21. Kellendonk C, Opherk C, Anlag K, Schütz G, Tronche F. Hepatocyte-specific expression of Cre recombinase. Genesis (New York, NY: 2000) 2000; 26: 151-153.
22. Arshad MI, Piquet-Pellorce C, Filliol A, L'Helgoualc'h A, Lucas-Clerc C, Jouan-Lanhouet S et al. The chemical inhibitors of cellular death, PJ34 and Necrostatin-1, down-regulate IL-33 expression in liver. J Mol Med (Berl) 2015; 93: 867-878.
23. Houseman L, Edwards M, Phillips IR, Shephard EA. Isolation and culture of mouse hepatocytes: gender-specific gene expression responses to chemical treatments. Methods Mol Biol 2015; 1250: 3-12.
24. Sato M, Tanigawa M. Production of CETD transgenic mouse line allowing ablation of any type of specific cell population. Mol Reprod Dev 2005; 72: 54-67.
25. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.
26. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
27. Gentle IE, Wong WW, Evans JM, Bankovacki A, Cook WD, Khan NR et al. In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8. J Biol Chem 2011; 286: 13282-13291.
28. Estornes Y, Aguileta MA, Dubuisson C, De Keyser J, Goossens V, Kersse K et al. RIPK1 promotes death receptor-independent caspase-8-mediated apoptosis under unresolved ER stress conditions. Cell Death Dis 2014; 5: e1555.
29. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K et al. T cell activationassociated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994; 179: 1529-1537.
30. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology (Baltimore, MD) 1995; 21: 190-198.
31. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alphainduced apoptosis by NF-kappaB. Science 1996; 274: 787-789.
32. Liedtke C, Trautwein C. The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. Eur J Cell Biol 2012; 91: 582-589.
33. Kawasuji A, Hasegawa M, Horikawa M, Fujita T, Matsushita Y, Matsushita T et al. L-selectin and intercellular adhesion molecule-1 regulate the development of concanavalin A-induced liver injury. J Leukoc Biol 2006; 79: 696-705.
34. Wolf D, Hallmann R, Sass G, Sixt M, Kusters S, Fregien B et al. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1-relevance for concanavalin A-induced hepatitis. J Immunol 2001; 166: 1300-1307.
35. Tiegs G, Wolter M, Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1989; 38: 627-631.
36. Geisler F, Algül H, Paxian S, Schmid RM. Genetic inactivation of RelA/p65 sensitizes adult mouse hepatocytes to TNF-induced apoptosis in vivo and in vitro. Gastroenterology 2007; 132: 2489-2503.
37. Wroblewski R, Armaka M, Kondylis V, Pasparakis M, Walczak H, Mittrucker HW et al. Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice. Hepatology 2016; 64: 508-521.
38. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ 2007; 14: 400-410.
39. Kunstle G, Hentze H, Germann PG, Tiegs G, Meergans T, Wendel A. Concanavalin A hepatotoxicity in mice: tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation. Hepatology 1999; 30: 1241-1251.
40. Dondelinger Y, Aguileta MA, Goossens V, Dubuisson C, Grootjans S, Dejardin E et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 2013; 20: 1381-1392.
41. Ting AT, Bertrand MJ. More to life than NF-kappaB in TNFR1 signaling. Trends Immunol 2016; 37: 535-545.
42. Liedtke C, Bangen JM, Freimuth J, Beraza N, Lambertz D, Cubero FJ et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 2011; 141: 2176-2187.
43. Vucur M, Reisinger F, Gautheron J, Janssen J, Roderburg C, Cardenas DV et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep 2013; 4: 776-790.
44. Kondylis V, Polykratis A, Ehlken H, Ochoa-Callejero L, Straub BK, Krishna-Subramanian S et al. NEMO prevents steatohepatitis and hepatocellular carcinoma by inhibiting RIPK1 kinase activity-mediated hepatocyte apoptosis. Cancer Cell 2015; 28: 582-598.
45. Wong WW, Gentle IE, Nachbur U, Anderton H, Vaux DL, Silke J. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ 2010; 17: 482-487.
46. An J, Mehrhof F, Harms C, Lattig-Tunnemann G, Lee SL, Endres M et al. ARC is a novel therapeutic approach against acetaminophen-induced hepatocellular necrosis. J Hepatol 2013; 58: 297-305.
47. Takemoto K, Hatano E, Iwaisako K, Takeiri M, Noma N, Ohmae S et al. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminopheninduced acute liver failure. FEBS Open Bio 2014; 4: 777-787.
48. Zhang YF, He W, Zhang C, Liu XJ, Lu Y, Wang H et al. Role of receptor interacting protein (RIP)1 on apoptosis-inducing factor-mediated necroptosis during acetaminophen-evoked acute liver failure in mice. Toxicol Lett 2014; 225: 445-453.
49. Dara L, Johnson H, Suda J, Win S, Gaarde W, Han D et al. Receptor interacting protein kinase 1 mediates murine acetaminophen toxicity independent of the necrosome and not through necroptosis. Hepatology 2015; 62: 1847-1857.
50. Schneider AT, Gautheron J, Tacke F, Vucur M, Luedde T. Receptor interacting protein kinase-1 (RIPK1) in hepatocytes does not mediate murine acetaminophen toxicity. Hepatology 2016; 64: 306-308.
51. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119-132.
52. Ehlken H, Krishna-Subramanian S, Ochoa-Callejero L, Kondylis V, Nadi NE, Straub BK et al. Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout. Cell Death Differ 2014; 21: 1721-1732.